Agios Pharmaceuticals, Inc.
AGIONasdaqCIK 1439222HealthcareFiscal year ends Dec 31
Reports and events: 270 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-07-3009:56 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001439222-26-000118 |
| 2026-07-3006:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001439222-26-000115 |
| 2026-06-1816:13 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-275879 |
| 2026-04-2909:22 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001439222-26-000073 |
| 2026-04-2906:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001439222-26-000071 |
| 2026-04-2416:01 ET | DEF 14A | Proxy statementPeriod 2026-06-18 | 0001193125-26-177086 |
| 2026-02-1209:33 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001439222-26-000025 |
| 2026-02-1206:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001439222-26-000023 |
| 2026-01-1207:11 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001439222-26-000018 |
| 2025-10-3009:57 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001439222-25-000116 |
| 2025-10-3006:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001439222-25-000114 |
| 2025-08-0413:53 ET | 8-K | 7.01 Regulation FD disclosure | 0001439222-25-000090 |
| 2025-07-3110:29 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001439222-25-000089 |
| 2025-07-3106:38 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001439222-25-000087 |
| 2025-07-0807:01 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001439222-25-000076 |
| 2025-06-1816:31 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-25-142745 |
| 2025-05-0110:26 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001439222-25-000036 |
| 2025-05-0106:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001439222-25-000034 |
| 2025-04-2516:03 ET | DEF 14A | Proxy statementPeriod 2025-06-18 | 0001193125-25-096719 |
| 2025-02-1309:26 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001439222-25-000009 |
| 2025-02-1306:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001439222-25-000007 |
| 2025-02-1306:01 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-025524 |
| 2025-01-1307:01 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-004943 |
| 2025-01-0606:36 ET | 8-K | 7.01 Regulation FD disclosure | 0001193125-25-001809 |
| 2024-10-3109:20 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001439222-24-000138 |
| 2024-10-3106:56 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001439222-24-000136 |
| 2024-08-0109:49 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001439222-24-000121 |
| 2024-08-0107:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001439222-24-000117 |
| 2024-06-2017:06 ET | 8-K | 5.07 Shareholder vote results | 0001193125-24-164555 |
| 2024-05-2807:09 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-147583 |
| 2024-05-0209:20 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001439222-24-000069 |
| 2024-05-0207:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001439222-24-000067 |
| 2024-04-2616:02 ET | DEF 14A | Proxy statementPeriod 2024-06-20 | 0001193125-24-117951 |
| 2024-02-1510:33 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001439222-24-000035 |
| 2024-02-1507:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001439222-24-000032 |
| 2024-01-0807:58 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-003920 |
| 2023-11-0209:20 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001439222-23-000140 |
| 2023-11-0207:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001439222-23-000138 |
| 2023-08-0309:20 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0001439222-23-000119 |
| 2023-08-0306:38 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001439222-23-000117 |
| 2023-06-1416:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-23-166855 |
| 2023-05-2516:02 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-23-154190 |
| 2023-05-0409:55 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0001439222-23-000065 |
| 2023-05-0407:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001439222-23-000063 |
| 2023-04-2616:03 ET | DEF 14A | Proxy statement | 0001193125-23-118490 |
| 2023-04-1907:26 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-23-105679 |
| 2023-03-0316:11 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-23-060031 |
| 2023-02-2310:35 ET | 10-K | Annual reportPeriod 2022-12-31 | 0001439222-23-000039 |
| 2023-02-2307:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001439222-23-000037 |
| 2023-01-0907:18 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-23-004143 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 26, 2026, 16:12 ET. Listed shows no prices and gives no investment advice.